Eli Lilly and Company (VIE:LLYC)
Austria · Delayed Price · Currency is EUR | Market Cap | 675.66B +10.3% |
| Revenue (ttm) | 55.51B +44.7% |
| Net Income | 17.58B +94.9% |
| EPS | 19.55 +96.0% |
| Shares Out | n/a |
| PE Ratio | 38.44 |
| Forward PE | 25.53 |
| Dividend | 5.37 (0.71%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 26 |
| Average Volume | 28 |
| Open | 784.90 |
| Previous Close | 785.60 |
| Day's Range | 753.00 - 784.90 |
| 52-Week Range | 539.10 - 965.00 |
| Beta | n/a |
| RSI | 37.57 |
| Earnings Date | Apr 30, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
As Investors Focus on Lilly's Foundayo, They May Be Overlooking Another Key Catalyst
Eli Lilly's Foundayo launch is drawing attention, but analysts say eloralintide and combination therapies could drive the next leg of growth.
Eli Lilly to Buy Ajax Therapeutics for Up to $2.3 Billion
Eli Lilly continued its recent buying spree, agreeing to pay up to $2.3 billion for Ajax Therapeutics in a deal that bolsters the drugmaker's blood-cancer portfolio.
Eli Lilly to acquire Ajax Therapeutics for up to $2.3 billion
Eli Lilly said on Monday it would buy privately-held blood cancer treatment developer Ajax Therapeutics for up to $2.3 billion in cash.
Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026 Based on i...
Lilly stock falls as Foundayo trails Novo's Wegovy in early uptake
Shares of Eli Lilly came under pressure on Friday after early prescription data for its newly launched weight-loss pill suggested a slower rollout compared with rival Novo Nordisk's competing product....
Lilly's obesity pill hits nearly 4000 prescriptions in second week after launch
Eli Lilly's newly launched oral weight loss drug was prescribed 3,707 times in the U.S. in the second week after its launch earlier this month, according to analysts citing IQVIA data.
‘BUYING OPPORTUNITIES': Investor reveals TOP stock picks amid uncertainty
BD8 Capital Partners CIO Barbara Doran discusses the market's rebound and retail investor re-entry on ‘Making Money.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #makingmoney ...
Eli Lilly Is More Than GLP-1 Drugs. The Stock Looks Attractive.
The acquisition of Kelonia Therapeutics, announced this week, is part of Lilly's expansion into cancer treatments.
Health insurers raise questions about Medicare program that will offer GLP-1s to seniors for $50
Some health insurers are pushing back against a new program that will allow Medicare beneficiaries to pay $50 per month for GLP-1 medications for weight loss.
Monday's Final Takeaways: LLY New Acquisition & AAL Shuts Down UAL Bid
Eli Lilly's (LLY) $7 billion acquisition of Kelonia Therapeutics and American Airlines (AAL) denying a United Airlines (UAL) acquisition bid take Sam Vadas and Marley Kayden's attention for Monday's f...
Eli Lilly Goes Atomic—But This Isn't About AI Servers
The drugmaker behind Prozac and Cialis is now exploring nuclear energy, signing a letter of intent with Indiana to support small modular reactors and advanced nuclear tech. The signal here isn't about...
Eli Lilly to buy Kelonia Therapeutics in up to $7 billion cancer immunotherapy drug deal
CNBC's Angelica Peebles reports the latest news on pharmaceuticals.
Eli Lilly to acquire Kelonia in $7 billion cancer therapy push
Eli Lilly said on Monday it will acquire privately held Kelonia Therapeutics in a deal worth up to $7 billion, as the drugmaker deepens its presence in next-generation cancer treatments. The agreement...
Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion
Eli Lilly said it has agreed to acquire biotech company Kelonia Therapeutics. Lilly will pay $3.25 billion upfront and up to $7 billion in total, the company said.
Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
Kelonia's lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 for relapsed/refractory multiple myeloma with clinical data recently highlighted...
Eli Lilly Stock Falls as It Closes in on a $2 Billion Deal. Here's Why.
Eli Lilly's deal for Kelonia, which develops blood cancer therapies, could come as early as Monday.
Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says
Eli Lilly is in advanced talks to acquire Kelonia Therapeutics for more than $2 billion, the Wall Street Journal reported on Sunday.
Eli Lilly Nears Deal for Cancer Biotech
Deal for Kelonia Therapeutics could come as soon as Monday.
These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.
A scientific report has raised questions about how much Leqimbi and Kisunla — the “breakthrough” Alzheimer's drugs that have hit the market in the last few years — really help slow the disease.
Novo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake
Reuters, citing IQVIA data, reported that Eli Lilly recorded 1,390 prescriptions for its newly launched obesity pill in the U.S. for the week ended April 10.
Lilly CEO sees weight-loss drugs reaching about half of potential users at peak
Weight-loss drugs may eventually reach only about 50% of the overweight and obese people who could benefit from them due to complexities of healthcare systems and financial constraints, Eli Lilly CEO...
Lilly's new GLP-1 pill is off to a ‘robust' start
Lilly's new GLP-1 pill had 1,390 prescriptions in its first week on the market.
Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson
XLRP is a severe, progressive genetic eye disease causing early-onset night blindness and peripheral vision loss, leading to legal blindness by age 40–45.
Lilly confirms date and conference call for first-quarter 2026 financial results announcement
INDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2026 financial results on April 30, 2026. Lilly will also conduct a conference call that ...
Eli Lilly Reveals Results of Late-Stage Study for Type 2 Diabetes Treatment
Eli Lilly's late-stage study of the efficacy and safety of a treatment for type 2 diabetes has produced positive results.